clinical trial · NCT04406649
A Study to Evaluate the Safety of STS101 in the Acute Treatment of Migraine
Satsuma Pharmaceuticals, Inc.·phase3·completed·n = 482
MigraineMigraine With AuraMigraine Without AuraDihydroergotamine
brief summary
Study STS101-003 is a multi-center, multiple dose (PRN), open-label, 12-month study to evaluate the safety and tolerability of STS101 (dihydroergotamine nasal powder) in the acute treatment of migraine.
started
Sep 14, 2020
primary completion
Jan 16, 2023
completion
Jan 16, 2023
last updated
Jul 3, 2023
detailed description
The ASCEND trial is a multi-center, multiple dose (PRN), open-label, 12-month study to evaluate the safety and tolerability of STS101 (dihydroergotamine nasal powder) in the acute treatment of migraine.
official title
An Open-Label, 12-Month Study to Evaluate the Safety and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol